Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02803229 · ClinicalTrials.gov registry record · Phase 2
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
A Phase 2 study of Cannabis Use Disorder and Attention Deficit/Hyperactivity Disorder, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT02803229 is a Phase 2 study of Cannabis Use Disorder and Attention Deficit/Hyperactivity Disorder that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 33 participants, below the 108-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02803229, a Phase 2 study of Cannabis Use Disorder and Attention Deficit/Hyperactivity Disorder, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed protocol is a double-blind, placebo-controlled outpatient study of the safety and benefit of Extended-release mixed amphetamine salt (Adderall-XR, MAS-XR) in the treatment of individuals with Cannabis Use Disorder (CUD) and Attention-deficit/Hyperactivity Disorder (ADHD). The investigators plan to enroll 50 and randomize 40 of these patients in the trial. The primary objective of the study is to determine the efficacy of MAS-XR in promoting cannabis abstinence among individuals with CUD and in promoting a decrease of ADHD symptoms.
Conditions Studied
Interventions
- DRUG Adderall-XR
- DRUG Matched placebo
Study Locations (1)
New York
- New York Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-07 |
| Est. Completion | 2020-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02803229
The ClinicalTrials.gov registry entry for NCT02803229 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (69% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cannabis Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Adderall-XR is the first listed.
NCT02803229 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02803229 about?
NCT02803229 is a clinical study titled "Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder". The proposed protocol is a double-blind, placebo-controlled outpatient study of the safety and benefit of Extended-release mixed amphetamine salt (Adderall-XR, MAS-XR) in the treatment of individuals with Cannabis Use Disorder (CUD) and Attention-deficit/Hyperactivity Disorder (ADHD). The investigat...
What is the current status of trial NCT02803229?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2016-07. Estimated completion is 2020-06.
What conditions does trial NCT02803229 study?
This clinical trial studies the following conditions: Cannabis Use Disorder, Attention Deficit/Hyperactivity Disorder.
What interventions are being tested in trial NCT02803229?
The interventions under investigation include: Adderall-XR (DRUG), Matched placebo (DRUG).
Who is sponsoring clinical trial NCT02803229?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02803229 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Longitudinal Outpatient Treatment for Cannabis Use Disorder
RECRUITING · Phase 2
-
A Study of Cannabidiol in Young Adult Cannabis Users
RECRUITING · Phase 2
-
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
RECRUITING · Phase 2
-
Cannabidiol and Cannabis Concentrate Users
RECRUITING · Phase 2
-
A Teleheath tDCS Approach to Decrease Cannabis Use
COMPLETED · Phase 2
-
UH3 Varenicline for Cannabis Use Disorder
COMPLETED · Phase 2
Explore more on PlainTrial
Cannabis Use Disorder
All registered trials for this condition
Attention Deficit/Hyperactivity Disorder
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.